Snapshot
Arecor awarded £2.8m from Innovate UK to accelerate fight against diabetes
About the company
Arecor is ‘advancing today’s therapies to enable healthier lives’ by developing a broad portfolio of therapies for its proprietary pipeline and in partnership with leading pharmaceutical and biotech companies
How it is doing 17 May 2021
Arecor is planning to debut on AIM with a £20mln IPO next month to boost its pipeline of diabetes treatment.
The biopharmaceutical group was recently awarded a £2.8mln grant from Innovate UK to support the Phase II development of AT247.
The candidate is an ultra-rapid acting insulin product based on the biopharma company’s proprietary Arestat technology platform.